Q-omics provides the consensus-scored TCP10L profile across patient tissues and cancer cell-line models. TCP10L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TCP10L is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, TCP10L RNA expression shows 14,380 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KICH, and TGCT as cancer lineages where TCP10L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCP10L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCP10L survival associations across molecular data types. TCP10L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCP10L RNA expression–survival associations across cancer types. High TCP10L expression shows unfavorable associations in COAD, DLBC and MESO, but favorable associations in UVM, LIHC and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for TCP10L RNA expression.
This table summarizes TCP10L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TCP10L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCP10L shows lower tumor expression in KICH, THCA, LIHC, CHOL and UCEC and higher tumor expression in BRCA. The KICH box plot shows higher TCP10L RNA expression in normal versus tumor tissue (log2 FC = −0.736, t-test p < 0.001).
This table shows molecular features associated with TCP10L in patient tissues and cancer cell lines. In patient samples, TCP10L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TCP10L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
